With the ink still drying on its latest acquisition, former Malvern-based drug maker  Endo International PLC is sending its AMS medical device unit off to the auction block.

Endo stands to lose nearly a billion dollars by saying goodbye to AMS after just three years and an ugly settlement, but there is apparently plenty of interest in the business, according to a new Wall Street Journal report. The unit produced $250 million in revenues over six months, some 19 percent of the parent company’s total inflows.

Endo’s busy year has included AMS’ $830 million vaginal mesh insert injury settlement, its $1.6 billion inversion takeover of Paladin Labs Inc., and a $600 million buyout of Dava Pharmaceuticals Inc.

AMS came to Endo with a price tag of $2.9 billion and may now sell for around $2 billion, the article noted.

Read more about the potential sell-off in The Wall Street Journal here.